Limits...
Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Territo PR, Maluccio M, Riley AA, McCarthy BP, Fletcher J, Tann M, Saxena R, Skill NJ - BMC Med Imaging (2015)

Bottom Line: This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα.In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative.Consequently 11C-acetate PET/CT is well suited to study (1) HCC emergence/progression in patients and (2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Radiology and Imaging Sciences, Indianapolis, IN, 46202, USA. pterrito@iupui.edu.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2(-/-) mice in order to facilitate therapeutic translational studies from bench to bedside.

Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2(-/-) mice (n = 3/tracer) with HCC and 12 m MDR2(-/+) control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2(-/-) (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list.

Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2(-/-) mice. In contrast, hepatic 11C-acetate metabolism was significantly elevated in MDR2(-/-) mice when compared to MDR2(-/+) controls. Serum AFP and LPA levels increased in MDR2(-/-) mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative.

Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2(-/-) mice and patients with underlying liver disease. Consequently 11C-acetate PET/CT is well suited to study (1) HCC emergence/progression in patients and (2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

Show MeSH

Related in: MedlinePlus

11C-acetate PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild type mice. 11C-acetate PET/CT imaging was performed on 12 mo MDR2−/− and FVB control mice. a) Representative 11C-acetate PET/CT parametric (ml/g.min) images of MDR2−/− mouse. b) Representative 11C-acetate PET/CT parametric (ml/g.min) images of FVB control mouse. c) Hepatic 11C-acetate metabolic rate was significantly greater in MDR2−/− mouse when compared to controls (student’s t test p < 0.05, n = 3/group)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4493966&req=5

Fig4: 11C-acetate PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild type mice. 11C-acetate PET/CT imaging was performed on 12 mo MDR2−/− and FVB control mice. a) Representative 11C-acetate PET/CT parametric (ml/g.min) images of MDR2−/− mouse. b) Representative 11C-acetate PET/CT parametric (ml/g.min) images of FVB control mouse. c) Hepatic 11C-acetate metabolic rate was significantly greater in MDR2−/− mouse when compared to controls (student’s t test p < 0.05, n = 3/group)

Mentions: Elevated substrate level oxidative phosphorylations, in the absence of glycolytic contributions, have been reported in clinical HCC [37–40]. To monitor substrate level oxidative phosphorylation in HCC, dynamic 11C-acetate PET/CT scans were conducted on MDR2−/− and control mice. Hepatic 11C-acetate metabolic rates were statistically higher in MDR2−/− (0.62 ± 0.04 ml/g.min) mice when compared to wild-type control mice (0.49 ± 0.02 ml/g.min, p = 0.039, n = 3/group) (see Fig. 4a-c), and no differences were observed between MDR2−/+ and FVB control (p > 0.05).Fig. 4


Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Territo PR, Maluccio M, Riley AA, McCarthy BP, Fletcher J, Tann M, Saxena R, Skill NJ - BMC Med Imaging (2015)

11C-acetate PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild type mice. 11C-acetate PET/CT imaging was performed on 12 mo MDR2−/− and FVB control mice. a) Representative 11C-acetate PET/CT parametric (ml/g.min) images of MDR2−/− mouse. b) Representative 11C-acetate PET/CT parametric (ml/g.min) images of FVB control mouse. c) Hepatic 11C-acetate metabolic rate was significantly greater in MDR2−/− mouse when compared to controls (student’s t test p < 0.05, n = 3/group)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4493966&req=5

Fig4: 11C-acetate PET/CT imaging of MDR2−/−, MDR2−/+ and FVB wild type mice. 11C-acetate PET/CT imaging was performed on 12 mo MDR2−/− and FVB control mice. a) Representative 11C-acetate PET/CT parametric (ml/g.min) images of MDR2−/− mouse. b) Representative 11C-acetate PET/CT parametric (ml/g.min) images of FVB control mouse. c) Hepatic 11C-acetate metabolic rate was significantly greater in MDR2−/− mouse when compared to controls (student’s t test p < 0.05, n = 3/group)
Mentions: Elevated substrate level oxidative phosphorylations, in the absence of glycolytic contributions, have been reported in clinical HCC [37–40]. To monitor substrate level oxidative phosphorylation in HCC, dynamic 11C-acetate PET/CT scans were conducted on MDR2−/− and control mice. Hepatic 11C-acetate metabolic rates were statistically higher in MDR2−/− (0.62 ± 0.04 ml/g.min) mice when compared to wild-type control mice (0.49 ± 0.02 ml/g.min, p = 0.039, n = 3/group) (see Fig. 4a-c), and no differences were observed between MDR2−/+ and FVB control (p > 0.05).Fig. 4

Bottom Line: This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα.In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative.Consequently 11C-acetate PET/CT is well suited to study (1) HCC emergence/progression in patients and (2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Radiology and Imaging Sciences, Indianapolis, IN, 46202, USA. pterrito@iupui.edu.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2(-/-) mice in order to facilitate therapeutic translational studies from bench to bedside.

Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2(-/-) mice (n = 3/tracer) with HCC and 12 m MDR2(-/+) control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2(-/-) (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list.

Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2(-/-) mice. In contrast, hepatic 11C-acetate metabolism was significantly elevated in MDR2(-/-) mice when compared to MDR2(-/+) controls. Serum AFP and LPA levels increased in MDR2(-/-) mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative.

Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2(-/-) mice and patients with underlying liver disease. Consequently 11C-acetate PET/CT is well suited to study (1) HCC emergence/progression in patients and (2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

Show MeSH
Related in: MedlinePlus